Cambridge Study Reveals Brain Mechanisms Behind Weight Loss Treatments

Researchers from the University of Cambridge have uncovered why both activating and blocking the same brain receptor can promote weight loss. Their study, published in Nature Metabolism, reveals that the outcome depends on which part of the brain is targeted. Activating the receptor in the brainstem reduces appetite, while blocking it in the hypothalamus produces weight loss through a different mechanism.

The study focused on the glucagon-like peptide 1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR), both of which are targeted by modern weight loss drugs. Medications like Wegovy and Ozempic activate GLP-1R, while others like Mounjaro and Zepbound activate GIPR. Interestingly, some treatments, such as MariTide, block GIPR yet still promote weight loss.

The researchers used genetically modified mice to explore how these receptors function in different brain regions. They found that GIPR agonists work primarily through the brainstem to reduce appetite, whereas GIPR antagonists act through the hypothalamus by releasing a 'brake' on fullness signals. This dual mechanism explains the effectiveness of different drug combinations.

The findings suggest that combining GIPR antagonists with GLP-1-based medicines could enhance weight loss effects. Dr. Jo Lewis, the study's first author, emphasized the importance of understanding brain circuits in obesity treatment, noting that these drugs have significant effects on specific brain circuits regulating appetite.

This research was supported by the Medical Research Council and Wellcome, and it highlights the potential for developing more effective obesity treatments by targeting specific brain pathways.